Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases

Leukemia & Lymphoma
G MeloniF Mandelli

Abstract

Since 1988 we have treated a first group of 14 patients with recombinant interleukin-2 (rIL-2), which was previously published, and 6 other consecutive patients affected by refractory or relapsed acute myelogenous leukemia (AML) with >5% and < or = 30% bone marrow blasts, but not suitable for further chemotherapy. The rIL-2 schedule consisted of four 5-day high-dose cycles administered by continuous infusion with a 72-hour rest period between each cycle. Patients who achieved a response received a lower dose of subcutaneous rIL-2 maintenance treatment administered for 5 days every month. Following high-dose rIL-2, 11/20 patients (55%) obtained a complete remission (CR). Six remain in persistent CR after a median follow-up time of 50 months (9, 33, 49, 51, 52, 87 months, respectively); the length of remission is the longest in the natural history of the disease for each individual patient. One patient with stable disease at the end of rIL-2 induction is alive and well, with a stable number of blasts in the bone marrow, 18 months later. These 7 patients continue maintenance treatment with subcutaneous rIL-2. Close clinical and laboratory monitoring reveal that side effects are acceptable and no toxic deaths have been recorded. Th...Continue Reading

References

Jun 1, 1991·The Annals of Thoracic Surgery·A BorgeatD Schwander
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S AmadoriF Mandelli
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
Apr 1, 1995·Leukemia Research·R Foa
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Foa
Jul 1, 1993·Stem Cells·F MandelliG Meloni
Dec 11, 1987·Health Progress·P McMillen

❮ Previous
Next ❯

Citations

Oct 16, 1999·British Journal of Haematology·D K Webb
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
May 6, 2014·Current Treatment Options in Oncology·Peter H Wiernik
Apr 24, 2002·Clinical Lymphoma·Chadi Nabhan, Martin S Tallman
Apr 18, 2006·Seminars in Hematology·Sherif S Farag, Michael A Caligiuri
May 18, 2001·Best Practice & Research. Clinical Haematology·G F TorelliR Foà
Jan 28, 2017·Case Reports in Hematology·Pankit VachhaniEunice S Wang
Mar 29, 2018·Expert Review of Hematology·Mansour Alfayez, Gautam Borthakur
Apr 9, 2019·JCO Precision Oncology·Mansour AlfayezCourtney D DiNardo

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.